Cancer drug olaparib tested for rare pancreatic tumor
NCT ID NCT05286827
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare pancreatic cancer. Participants took olaparib pills twice daily for up to 2 years. The study was terminated early after enrolling only 5 people, so it is not known if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (Lynparza)
- What this could lead to
- If it works, this could point toward a treatment option for a rare and hard-to-treat pancreatic cancer.
- What could go wrong
- The trial was terminated early with only 5 participants, so results are very limited. It is unclear if olaparib is effective for this cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ACINAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail shows promise against tough pancreatic cancer
- Experimental combo aims to overcome drug resistance in metastatic cancers
- Immunotherapy duo takes on rare tumors
- New hope for BRCA pancreatic cancer? trial tests adding cisplatin to standard chemo
- New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
- Experimental drug cocktail targets Hard-to-Treat cancers